{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Family-Centered Advance Care Planning in Patients With Breast Cancer: A Randomized Controlled Trial in China.","author":[{"@type":"Person","name":"Ruoyan Wang"},{"@type":"Person","name":"Rui Gao"},{"@type":"Person","name":"Saixiao Pei"},{"@type":"Person","name":"Chao Zhang"},{"@type":"Person","name":"Dongli Li"},{"@type":"Person","name":"Yongqing Shen"}],"datePublished":"2026","isPartOf":{"@type":"Periodical","name":"Omega"},"identifier":"https://doi.org/10.1177/00302228261421702","description":"\n Objective:\n To evaluate the feasibility, acceptability, and effects of family-centered advance care planning (ACP) in patients with breast cancer.\n Methods:\n In this randomized controlled trial, 80 breast cancer patients were assigned to either a family-centered ACP group or a standard care group. Outcomes were measured at baseline and one month after the intervention using the Advance Care Planning Acceptance Questionnaire (ACPQ), Templer Death Anxiety Scale (T-DAS), Functional Assessment of Cancer Therapy – Breast (FACT-B), and a self-designed questionnaire.\n Results:\n Compared to controls, the intervention group showed higher ACP acceptance and improved quality of life (excluding physical well-being and additional concerns), along with lower death anxiety and reduced preference for life-sustaining treatments and aggressive end-of-life care.\n Conclusion:\n Family-centered ACP is feasible and acceptable for breast cancer patients. It enhances ACP engagement, improves quality of life, and reduces death anxiety. This study was prospectively registered in a publicly accessible clinical trial registry.\n ","url":"https://innscience.ca/en/community/literature/doi_10_1177_00302228261421702"}